<DOC>
	<DOCNO>NCT01562457</DOCNO>
	<brief_summary>This trial conduct Asia Europe . The aim trial evaluate intra-subject variability thromboelastographic parameter ( TEG速 ROTEM速 ) follow two administration activate recombinant human factor VII haemophilia patient non bleed state . The TEG速 parameter : R time ( Reaction Time ) , K time ( K Time ( arbitrary measurement ) ) , ( angle ) , MA ( Maximum Amplitude ) LY30 ( Lysis 30 min MA ) ROTEM速 parameter : CT ( Clotting Time ) , CFT ( Clot Formation Time ) , ( angle ) , MCF ( Maximum Clot Firmness ) LI60 ( Lysis index 60 min CT ) .</brief_summary>
	<brief_title>Intra-subject Variability Following Administrations Activated Recombinant Human Factor VII Haemophilia Patients Non-bleeding State</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Confirmed diagnosis congenital haemophilia A B FVIII : C ( Activated Coagulation Factor VIIa Clotting activity ) FIX : C ( Coagulation Factor IX Clotting activity ) one stage activity , respectively , less 5 % normal ( base medical record ) plus/minus inhibitor ( positive inhibitor status define 0.6 Bethesda unit ) Nonbleeding state ( i.e . clinical manifestation active bleed ) time administration trial product Known suspect allergy trial product component related product Known clinically relevant coagulation disorder insufficiency congenital haemophilia A B Platelet count 50,000 platelets/mcL Received haemostatic treatment ( e.g . Feiba ) within last 7 day prior administration trial product , except activate recombinant human factor VII</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>